Literature DB >> 17458550

Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide.

Tim Leiner, Christoph U Herborn, Mathias Goyen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17458550     DOI: 10.1007/s00330-007-0663-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


× No keyword cloud information.
  8 in total

1.  Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis.

Authors:  Phillip H Kuo; Emanuel Kanal; Ali K Abu-Alfa; Shawn E Cowper
Journal:  Radiology       Date:  2007-01-09       Impact factor: 11.105

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

3.  Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.

Authors:  Peter Marckmann; Lone Skov; Kristian Rossen; Anders Dupont; Mette Brimnes Damholt; James Goya Heaf; Henrik S Thomsen
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

4.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

Review 5.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.

Authors:  Jean-Marc Idée; Marc Port; Isabelle Raynal; Michel Schaefer; Soizic Le Greneur; Claire Corot
Journal:  Fundam Clin Pharmacol       Date:  2006-12       Impact factor: 2.748

Review 6.  Gadolinium deposition in nephrogenic fibrosing dermopathy.

Authors:  Alan S Boyd; John A Zic; Jerrold L Abraham
Journal:  J Am Acad Dermatol       Date:  2006-11-15       Impact factor: 11.527

7.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

Authors:  Whitney A High; Reed A Ayers; John Chandler; Gary Zito; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2006-11-09       Impact factor: 11.527

8.  Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide.

Authors:  Henrik S Thomsen
Journal:  Eur Radiol       Date:  2006-10-24       Impact factor: 5.315

  8 in total
  5 in total

Review 1.  Recent hot topics in contrast media.

Authors:  Henrik S Thomsen
Journal:  Eur Radiol       Date:  2010-12-07       Impact factor: 5.315

Review 2.  Advances in spinal cord MR angiography.

Authors:  W H Backes; R J Nijenhuis
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-17       Impact factor: 3.825

3.  Significant differences when using MDRD for GFR estimation compared to radionuclide measured clearance.

Authors:  A J Craig; A Britten; S D Heenan; A G Irwin
Journal:  Eur Radiol       Date:  2011-05-21       Impact factor: 5.315

Review 4.  Gadofosveset-enhanced magnetic resonance angiography.

Authors:  Mathias Goyen
Journal:  Vasc Health Risk Manag       Date:  2008

Review 5.  Gadolinium and nephrogenic systemic fibrosis: time to tighten practice.

Authors:  Iosif A Mendichovszky; Stephen D Marks; Clare M Simcock; Oystein E Olsen
Journal:  Pediatr Radiol       Date:  2007-10-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.